What is Myriad Genetics's prenatal health — revenue?

Myriad Genetics (MYGN) reported prenatal health — revenue of $41.9M in Q1 2026.

What does prenatal health — revenue mean?

This metric represents the total revenue generated from the sale of prenatal diagnostic testing services, including non-invasive prenatal screening products. It reflects the company's market penetration and commercial success within the reproductive health and genetic screening sector. Monitoring this revenue stream helps investors assess the growth trajectory and adoption rates of the firm's prenatal diagnostic portfolio.

Myriad Genetics MYGN Prenatal Health — Revenue

Other product segments

Cancer Care Continuum

$120.2M—

Hereditary Cancer

$96.8M+2.5%

Prenatal

$44.9M0.0%

Mental Health

$38.3M—

Similar metrics at other companies

BLLNPrenatal — Revenue

$96.53M+72.1%

CDNAProduct revenue — Total Revenue

$10.35M-4.3%

OSURProducts and services — Net revenues

$26.38M-9.0%

GRALScreening revenue — Total Revenue

$39.83M+36.7%

OSURRisk Assessment Testing — Net revenues

$0-100%

GHScreening — Total Revenue

$41.59M+633%

Other financials

Income statement

See full

Revenue$200.4M+2.3%

Gross profit$137.6M+2.5%

Operating income-$30.7M-5.9%

Net income-$34.1M-34,000%

EPS (diluted)-$0.36—

Balance sheet

See full

Cash & equivalents$126.0M+24.8%

Total debt$211.5M+34.2%

Total equity$337.4M-52.1%

Total assets$673.7M-33.0%

Cash flow

See full

Operating cash flow-$15.7M+3.7%

CapEx$18.8M+181%

Free cash flow-$19.7M+65.1%

Valuation

See full

Market cap$512.85M+13.1%

Enterprise value$598.35M+17.3%

P/S0.6×+0.1×

Profitability

See full

Gross margin70%0.0pp

Operating margin-46.9%-88.3pp

Net margin-48.2%-72.9pp

FCF margin-17%—

Returns & leverage

See full

Return on equity-76.7%-98.4pp

Debt / equity0.6×+0.4×

Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's prenatal health — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Myriad Genetics's prenatal health — revenue?: Myriad Genetics (MYGN) reported prenatal health — revenue of $41.9M in Q1 2026.
What does prenatal health — revenue mean?: This metric represents the total revenue generated from the sale of prenatal diagnostic testing services, including non-invasive prenatal screening products. It reflects the company's market penetration and commercial success within the reproductive health and genetic screening sector. Monitoring this revenue stream helps investors assess the growth trajectory and adoption rates of the firm's prenatal diagnostic portfolio.